Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Thaker

Showing results (171-180 of 237) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|February 6, 2021
Impact of employment and insurance status on distress in gynecologic oncology patientsLindsay M Kuroki, David H Morris, Molly Greenwade, et al.
Gynecologic Oncology|March 2, 2021
A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancyMary M Mullen, Tyler R McKinnish, Mark A Fiala, et al.
Gynecologic Oncology Reports|March 5, 2021
Obese endometrial cancer survivors' perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventionsElise M Wilson, Abigail S Zamorano, Jingxia Liu, et al.
Gynecologic Oncology|July 7, 2023
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, et al.
Gynecologic Oncology|February 19, 2025
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysisAyesha B Alvero, Sharon Wu, Alex Farrell, et al.
Gynecologic Oncology|June 18, 2021
Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trialAbigail S Zamorano, Elise M Wilson, Jingxia Liu, et al.
Scientific Reports|June 3, 2021
Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factorsSnehal Bindra, Marlon A McGill, Marina K Triplett, et al.
Psychoneuroendocrinology|April 21, 2019
Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patientsMichaela G Cuneo, Angela Szeto, Andrew Schrepf, et al.
Gynecologic Oncology Reports|June 25, 2021
Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancerE A Johns, J A Stanley, M D Toboni, et al.
Gynecologic Oncology|March 6, 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group studySusana M Campos, William E Brady, Katherine M Moxley, et al.
Pageof 24

Showing results (171-180 of 237) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|February 6, 2021
Impact of employment and insurance status on distress in gynecologic oncology patientsLindsay M Kuroki, David H Morris, Molly Greenwade, et al.
Gynecologic Oncology|March 2, 2021
A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancyMary M Mullen, Tyler R McKinnish, Mark A Fiala, et al.
Gynecologic Oncology Reports|March 5, 2021
Obese endometrial cancer survivors' perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventionsElise M Wilson, Abigail S Zamorano, Jingxia Liu, et al.
Gynecologic Oncology|July 7, 2023
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, et al.
Gynecologic Oncology|February 19, 2025
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysisAyesha B Alvero, Sharon Wu, Alex Farrell, et al.
Gynecologic Oncology|June 18, 2021
Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trialAbigail S Zamorano, Elise M Wilson, Jingxia Liu, et al.
Scientific Reports|June 3, 2021
Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factorsSnehal Bindra, Marlon A McGill, Marina K Triplett, et al.
Psychoneuroendocrinology|April 21, 2019
Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patientsMichaela G Cuneo, Angela Szeto, Andrew Schrepf, et al.
Gynecologic Oncology Reports|June 25, 2021
Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancerE A Johns, J A Stanley, M D Toboni, et al.
Gynecologic Oncology|March 6, 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group studySusana M Campos, William E Brady, Katherine M Moxley, et al.
Pageof 24